Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
pd-1 antibody expressing mesothelin specific car-t cells (1 trial)
Brexucabtagene autoleucel (Tecartus) (1 trial)
Lymphoma (Phase 1)
Lymphoma, B-Cell (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Neoplasms (Phase 2)
Trials (2 total)
Trial APIs (2 total)